Business
BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference
PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage
About this update from Bridgebio Pharma, Inc.
[{"type":"text","content":"PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that the updated six month results from Cohort 5 in PROPEL2, a Phase 2 trial of the investigational therapy, infigratinib in children with achondroplasia will be featured in an oral presentation at the Endocrine Society (ENDO) 2023 Annual Conference, taking place in Chicago, Illinois on June 15 – 18, 2023. At ENDO 2023, BridgeBio will also present additional data from its achondroplasia program and nonclinical results from studies in hypochondroplasia. Furthermore, the Company will share updates from its autosomal dominant hypocalcemia type 1 (ADH1) program, including 18 month data from its ongoing Phase 2 study of encaleret in ADH1 and its sponsored hypoparathyroidism genetic testing program. To access the oral presentation and poster materials following the Company’s participation at ENDO 2023, please visit https://investor.bridgebio.com/presentations. Achondroplasia oral presentation and poster details: Oral infigratinib treatment is well tolerated and significantly increases height velocity in children with achondroplasia: Month 6 results from the PROPEL 2 dose-finding studyPresenter: Ravi Savarirayan, M.D., Ph.D., clinical geneticist and group leader of molecular therapies research at the Murdoch Children’s Research Institute in Australia, the lead investigator for PROPEL2Oral presentation date & time: Saturday, June 17 at 4:00 pm CTLocation: W-184BC, McCormick PlaceSession title: Late Breaking IISession number: OR27-03 Low-dose infigratinib, an oral selective fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, demonstrates activity in murine models of achondroplasia and hypochondroplasiaPresenter: Elena Muslimova, Ph.D., medical director of skeletal dysplasias program at BridgeBioOral presentation date & time: Saturday, June 17 at 4:30 pm CTLocation: W-178B, McCormick PlaceSession title: Update on pediatric growth disordersSession number: OR21-05 PROPEL, PROPEL 2 and PROPEL OLE studies of infigratinib in children with achondroplasia: design and status of 3 ongoing trialsPoster presentation date & time: Thursday, June 15 at 12:30 pm CTLocation: Board no. THU-165, ENDOExpo Hall, McCormick...